Victoria Eatwell Sells 2,592 Shares of 2seventy bio, Inc. (NASDAQ:TSVT) Stock

2seventy bio, Inc. (NASDAQ:TSVT) CFO Victoria Eatwell sold 2,592 shares of the stock in a transaction that occurred on Monday, March 17th. The shares were sold at an average price of $4.95, for a total value of $12,830.40. Following the transaction, the chief financial officer now owns 444,387 shares of the company’s stock, valued at $2,199,715.65. This represents a 0.58 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link.

2seventy bio Stock Down 0.2 %

TSVT stock opened at $4.95 on Friday. The business’s fifty day simple moving average is $2.94 and its two-hundred day simple moving average is $3.71. 2seventy bio, Inc. has a twelve month low of $2.29 and a twelve month high of $5.99. The firm has a market cap of $255.36 million, a price-to-earnings ratio of -2.66 and a beta of 1.73.

Analysts Set New Price Targets

TSVT has been the subject of a number of research reports. Morgan Stanley lowered their target price on 2seventy bio from $6.00 to $5.00 and set an “equal weight” rating for the company in a research report on Friday, March 14th. Weiss Ratings restated a “sell (d-)” rating on shares of 2seventy bio in a research report on Friday, March 7th. Leerink Partners restated a “market perform” rating and issued a $5.00 price target (down from $9.00) on shares of 2seventy bio in a research report on Tuesday, March 11th. Finally, Leerink Partnrs downgraded 2seventy bio from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, March 11th. One research analyst has rated the stock with a sell rating, four have assigned a hold rating, two have assigned a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Hold” and an average target price of $6.67.

Institutional Trading of 2seventy bio

A number of hedge funds and other institutional investors have recently bought and sold shares of TSVT. Bank of America Corp DE increased its stake in 2seventy bio by 317.1% in the fourth quarter. Bank of America Corp DE now owns 2,515,897 shares of the company’s stock worth $7,397,000 after purchasing an additional 1,912,771 shares during the period. Regeneron Pharmaceuticals Inc. purchased a new stake in 2seventy bio in the fourth quarter worth $3,689,000. Toronto Dominion Bank purchased a new position in shares of 2seventy bio during the fourth quarter valued at $2,352,000. Western Standard LLC increased its stake in shares of 2seventy bio by 175.7% during the fourth quarter. Western Standard LLC now owns 788,350 shares of the company’s stock valued at $2,318,000 after buying an additional 502,419 shares during the period. Finally, Point72 Asset Management L.P. purchased a new position in shares of 2seventy bio during the fourth quarter valued at $913,000. Hedge funds and other institutional investors own 93.90% of the company’s stock.

About 2seventy bio

2seventy bio, Inc, a cell and gene therapy company, focuses on the research, development, and commercialization of treatments for cancer in the United States. The company's products pipeline includes Abecma, a chimeric antigen receptor T-cell product candidates for the treatment of multiple myeloma.